Abstract A process for producing anti-IL-2 antibody from hybridoma cells generated by fusing activated, IL-2 immunized, murine lymphocyte cells with neoplastic murine myeloma cells. Fusion is accomplished by mixing the two cell lines together in the presence of a fusing agent. After fusion, the hybridoma cells are cultured in vitro in a supplemented tissue culture medium to thereby produce anti-IL-2 antibody. Also, the hybridoma cells are cloned by a limiting dilution procedure to isolate even more potent sources of anti-IL-2 antibody. Anti-IL-2 antibody is then purified from either tissue culture medium conditioned by hybridoma cells, or from peritoneal ascites of mice challenged with hybridoma cells.
An anti-IL-2 antibody produced by: immunizing murine B-lymphocyte cells with IL-2; activating said immunized murine B-lymphocyte cells with a B-cell mitogen; fusing said activated murine B-lymphocyte cells with murine myeloma cells; culturing said hybridoma anti-IL-2 antibody producing cells under conditions suitable for antibody production; and recovering the anti-IL-2 antibody produced by said anti-IL-2 antibody producing cells.
Claim 2
Dependent Claim
56 words
An anti-IL-2 antibody produced by: immunizing murine B-lymphocyte cells with IL-2; activating said immunized murine B-lymphocyte cells with a B-cell mitogen; fusing said activated murine B-lymphocyte cells with murine myeloma cells; culturing said hybridoma anti-IL-2 antibody producing cells under conditions suitable for antibody production; and recovering the anti-IL-2 antibody produced by said anti-IL-2 antibody producing cells.
Claim 3
Dependent Claim
15 words
The anti-IL-2 antibody of claim 1, wherein said B-lymphocyte cells are from the BALB/c mice.
Claim 4
Dependent Claim
27 words
The anti-IL-2 antibody of claim 1, wherein said hybridoma anti-IL-2 antibody producing cells include cells selected from the group consisting essentially of 4E12, 4E12B2 and 4E12B2D10 cells.